Moreover, patients with poor ovarian reserve prefer considering minimal stimulation protocol, and GnRH antagonist protocols are applied to "poor responders" and women at high-risk of developing OHSS, thus oocyte/embryo quality and development was inferior to that of the agonist group. The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.